Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy
Abstract Background Since the ToGA trial, trastuzumab-based chemotherapy is the standard treatment for HER2 positive stage IV gastric cancer. However, it is not yet clear whether surgical resection after trastuzumab-based chemotherapy (conversion surgery) can improve survival of HER2 positive stage...
Saved in:
| Main Authors: | Koichi Hayano, Hiroki Watanabe, Takahiro Ryuzaki, Naoto Sawada, Gaku Ohira, Masayuki Kano, Masaya Uesato, Hisahiro Matsubara |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Japan Surgical Society
2020-09-01
|
| Series: | Surgical Case Reports |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40792-020-00984-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports
by: Yan Meng, et al.
Published: (2025-08-01) -
Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
by: Junxiao Wang, et al.
Published: (2025-07-01) -
Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients
by: Zohreh Gheibipour, et al.
Published: (2025-07-01) -
Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01) -
Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)